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Endometrial cancer is the most common gynecological cancer. Estrogen-dependent endometrioid carcinoma is the most common
type of endometrial cancer, and alterations in the expression of PTEN and K-ras have been associated with this disease. To study
the roles of Pten and K-ras in endometrial cancer, we generated Pten ablation and oncogenic K-ras mutation in progesterone
receptor positive cells (PRcre/+Ptenf/fK-rasG12D). Double mutant mice dramatically accelerated the development of endometrial
cancer compared to a single mutation of either gene. Histological analysis showed that all of the 1-month old double mutant
female mice developed endometrial cancer with myometrial invasion. The expression of PR was downregulated in double mutant
mice compared to a single mutation of either gene which resulted in decreased suppression of estrogen signaling. Therefore, these
results suggest a synergistic eﬀe c to fd y s r e g u l a t i o no ft h ePten and K-ras signaling pathways during endometrial tumorigenesis.
1.Introduction
Endometrial cancer is the most common type of gyne-
cological cancer in the United States with approximately
40100 cases diagnosed and about 7470 deaths from the
disease each year [1]. Therefore, there is great interest in
identifying novel ways to treat and prevent this disease.
Estrogen-dependent endometrioid carcinoma is the most
common type of endometrial cancer. An increased incidence
of endometrial cancer has been found in association with
prolonged, unopposed estrogen (E2) exposure [2, 3]a n d
alterations in the expression of the tumor suppressor gene,
PTEN, as well as the oncogenes, β-catenin and Ras [4, 5].
Currently, progesterone (P4) therapy is used as a means to
prevent the development of endometrial cancer associated
with unopposed E2 as a means to block E2 actions [6].
The uterus consists of heterogeneous cell types that
undergo dynamic changes in response to the ovarian steroid
hormones E2 and P4 to support embryo development and
implantation. E2 stimulates the proliferation of epithelial
cellsinthemouseuterus[7,8].Incontrast,P4isinhibitoryto
this E2-mediated proliferation of the luminal and glandular
epithelial cells. However, P4, alone or in conjunction with
E2, leads to uterine stromal cell proliferation [8–10]. The
ability of the ovarian steroid hormones to regulate uterine
cellproliferationdependsupontheabilityofhormonalstim-
ulation to regulate growth factor communication networks
between the uterine stroma and epithelium. For instance, P4
attenuates E2-stimulated uterine epithelial cell proliferation
by regulating uterine stromal cell gene expression [11]. An
imbalance caused by increased E2 action and/or decreased
P4 action can result in abnormal endometrial proliferation
and endometrial adenocarcinoma. Therefore, elucidating
the molecular mechanisms by which the steroid hormones
controluterinephysiologyisimportanttounderstandingthe
pathology of these diseases.
Two common mutations that occur in endometrial can-
cer are in the tumor suppressor Pten and the oncogene K-ras2 Journal of Oncology
[4, 5]. K-ras encodes a guanine nucleotide binding protein of
21kDa that has a central role in the regulation of cell growth
and diﬀerentiation by transducing signals from activated
transmembrane receptors. It has been shown to be mutated
in 10%–30% of endometrial cancers [4]. These mutations
have been found in all grades of endometrioid carcinoma
and have been reported in complex atypical hyperplasia,
suggesting a relatively early role for K-ras mutations in
endometrial tumorigenesis [12]. PTEN (phosphatase and
tensin homologue deleted from chromosome 10) is one
of the most frequently mutated tumor suppressor genes
in human cancers [13, 14]. PTEN is completely lost or
mutated in >50% of primary endometrioid endometrial
cancer [15] and in at least 20% of endometrial hyperplasias,
the precancerous lesions of the endometrium [15, 16].
Thus, loss of PTEN is a very early event in the multistep
processleadingtoendometrioidendometrialcancer[16,17].
Phosphoinositide 3-kinases (PI3K) regulates a number of
cellular functions through the activation of Akt [18]. PTEN
actsasanegativeregulatorofPI3Ksignaling[19].Previously,
loss of Pten (either as a heterozygote or by uterine speciﬁc
ablation) has been shown to induce endometrial cancer in
mice highlighting its important role in cancer development
[20, 21]. This mutation and subsequent Akt activation
resulted in the activation of ERα-dependent pathways that
play an important role in the tumorigenesis of endometrial
cancer [21]. Interestingly, the PTEN/PI3K/AKT signaling
pathway can also be activated by E2 suggesting a complex
interaction between these two signaling pathways [22].
In this study, we utilized conditional Pten ablation and
oncogenicK-rasmutationintheuteriofmicetodemonstrate
a synergistic eﬀect of dysregulation of the Pten and K-
ras signaling pathways during endometrial tumorigenesis.
Pten ablation and oncogenic K-ras mutation dramatically
accelerated the development of endometrial cancer com-
pared to single mutation of either gene. Thus, these results
demonstrate the importance of Pten and K-ras regulation in
the tumorigenesis of endometrial cancer.
2.MaterialsandMethods
2.1. Animals. Mice were maintained in the designated ani-
mal care facility at Baylor College of Medicine according to
the institutional guidelines for the care and use of laboratory
animals. PRCre/+ mice were previously generated [23]. The
Ptenf/f were acquired from Dr. Hong Wu (University of
California, Los Angeles, Los Angeles, CA) [24]. The lox-
stop-Lox KrasG12D mice were acquired from Dr. Tyler Jacks
(MIT, Cambridge, MA) [25]. Mice of various genotypes
were sacriﬁced at 2 and 4 weeks of age. At the time of
dissection, uterine tissues were placed in the appropriate
ﬁxative or ﬂash frozen and stored at −80◦C. For the
genotyping of the oncogenic K-ras mutation, total RNA
was isolated from uterus according to, Qiagen minieasy kit
protocol. cDNA was generated from RNA samples by reverse
transcription, followed by PCR ampliﬁcation using primers
K-ras1S, 5 -GCCATTTCGGACCCGGAGCGA and K-ras1A,
5 -CCTACCAGGACCATAGGCACATC. RNA expression of
wild-type K-ras and mutant K-ras G12D was determined by
digestion of 5μL of the reverse transcription-PCR products
with HindIII for 1 hour at 37◦C. The restriction products
were resolved in a 2% agarose gel. The mutant K-ras G12D
allele contains a HindIII restriction site engineered in exon 1,
whichisabsentinthewild-typeallele.Therefore,digestionof
the488-bpproductsgenerates300-bpand148-bprestriction
fragments in the mutant but not in the wild-type PCR
product.
2.2. Western Blot Analysis. Samples containing 15μgo f
proteins were applied to SDS-PAGE. The separated proteins
were transferred onto a polyvinylidene diﬂuoride membrane
(Millipore Corp., Bedford, MA). Membranes were blocked
overnight with 0.5% casein (wt/vol) in PBS with 0.1%
Tween 20 (vol/vol) (Sigma-Aldrich, St. Louis, MO) and
probed with anti-Akt(Santa Cruz Biotechnology, Inc., Santa
Cruz, CA), anti-phospho-Akt (Cell Signaling Technology,
Inc., Danvers, MA), anti-PR (DAKO Corp., Capinteria,
CA), or anti-ERα (DAKO Corp., Capinteria, CA) antibod-
ies. Immunoreactivity was visualized by incubation with
a horseradish peroxidase-linked secondary antibody and
treatment with ECL reagents. To control for loading, the
membrane was stripped and probed with anti-actin (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA) and developed
again.
2.3. Immunohistochemistry and TUNEL Assay. Uterine sec-
tions from paraﬃn-embedded tissue were cut at 5μm
and mounted on silane-coated slides, deparaﬁnized, and
rehydrated in a graded alcohol series. Sections were prein-
cubated with 10% normal serum in PBS (pH 7.5) and then
incubated with anti-PR antibody (DAKO Corp., Capinteria,
CA) or anti-ERα (DAKO Corp., Capinteria, CA) in 10%
normal serum in PBS (pH 7.5). On the following day,
sections were washed in PBS and incubated with a secondary
antibody (5μL/mL; Vector Laboratories, Burlingame, CA)
for 1 hour at room temperature. Immunoreacitivity was
detected using the Vectastain Elite ABC kit (Vector Labora-
tories, Burlingame, CA). The TUNEL assay was performed
according to manufacturer’s instructions using the Roche In
Situ Cell Death Detection Kit, Fluorescein (Roche, Boulder,
CO).
2.4. RNA Isolation and Quantitative Real-Time RT-PCR.
Total RNA was extracted from uterine tissues using the
Qiagen RNeasy total RNA isolation kit (Valencia, CA).
Quantitative real-time RT-PCR analysis was conducted on
isolated RNA. Expression levels of Ltf, Clca3, and C3 were
measured by real-time RT-PCR TaqMan analysis (Applied
Biosystems, Foster City, CA). cDNA was made from 1μg
of total RNA using random hexamers and M-MLV Reverse
Transcriptase (Invitrogen Corp., Carlsbad, CA). RT-PCR
was performed using RT-PCR Universal Master Mix reagent
(Applied Biosystems, Foster City, CA). All real-time RT-PCR
results were normalized against 18S RNA using ABI rRNA
control reagents. Statistical analyses were performed using
one-way ANOVA followed by Tukey’s post hoc multiple
range test with the Instat package from GraphPad (San
Diego, CA, USA).Journal of Oncology 3
3. Results
3.1. Generation of Pten Ablation and Oncogenic K-Ras Muta-
tion in the Murine Uterus. Homozygous Pten
−/− mouse
embryos die around E8.5 and heterozygous Pten+/− mice
develop numerous pathologies and have decreased longevity
[21, 26] making our ability to investigate the role of Pten
in the mouse uterus severely limited. Likewise, constitutive
activation of a K-ras mutation results in embryonic lethality
[27]. In order to achieve ablation of Pten and activation of
K-ras in the uterus, mice with ﬂoxed Pten (Ptenf/f)[ 24]
and mice with loxP-Stop-loxP-KrasG12D/+ (LSL-K-rasG12D/+)
[25] were bred to the PRCre mouse [23]. Using this mouse
withCrerecombinaseinsertedintotheprogesteronereceptor
(PR) locus, ﬂoxed genes are edited in PR expressing cells
including all compartments of the mouse uterus. This model
was previously used to ablate Pten in the uterus resulting
in endometrial adenocarcinoma [20]. Therefore, in order
to eﬀectively investigate the eﬀects of the Pten and K-ras
signaling pathways in endometrial cancer, mice with uterine
Pten ablation (PRcre/+Pten f/f; Pten d/d) and oncogenic K-ras
mutation (K-rasG12D) were generated and mated to generate
double mutant mice (PRcre/+Ptenf/fK-rasG12D; Ptend/dK-
rasG12D)[ 23–25]. Ablation of Pten in the Ptend/d mice was
assayed by Western blot and immunohistochemical analysis
(Figures 1(a) and 1(b)). PTEN protein was expressed in the
endometrium of Ptenf/f mice. However, the level of PTEN
protein was signiﬁcantly decreased in the uteri of Ptend/d
micedemonstratingeﬃcientablationofPten.Toconﬁrmthe
oncogenic K-ras mutation in the uterus, the PCR products
encompassingtheK-rasmutationweredigestedwithHindIII
(see Section 2). The mutant K-ras G12D allele contains a
HindIII restriction site engineered in exon 1, which is absent
in the wild-type allele. Therefore, digestion of the 488-bp
products generates 300-bp and 148-bp restriction fragments
inthemutantbutnotinthewild-typePCRproduct.Analysis
of the HindIII digestion revealed the presence of the 300-
bp and 148-bp fragments in the K-rasG12D but not in the
wild type uteri (Figure 1(c)). These results suggest that PR-
cre eﬃciently generated uterine Pten ablation and oncogenic
K-ras mutation.
3.2. Development of Vaginal Papillomas in Mice with the
Oncogenic K-ras Mutation in PR-Expressing Cells. Introduc-
tion of the oncogenic K-ras mutation in all PR-positive cells
resulted in the development of vaginal papillomas. Lesions
were present at the vaginal opening of K-rasG12D mice as
early as 2 months of age but were never observed in control
mice (Figure 2(a)). Examination of the histology of these
lesions revealed an abnormal vaginal architecture in the K-
rasG12D micecomparedtocontrols(Figure 2(b)).Thevaginal
epithelium exhibited increased keratinization accompanied
by disorganization of the vaginal lumen. In addition, there
was a decrease in the vaginal stroma. Interestingly, these
lesions remained benign, never developing into a cancerous
lesion. K-rasG12D mice did not show any pathological pheno-
type in the uterus. Proliferation was not aﬀected in the K-ras
mutant mice; however, there was increased apoptosis in the
K-rasG12D uteri compared to controls (Figure 2(c)).
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Figure 1: Analysis of conditionally ablated Pten and oncogenic
K-ras mutation in the murine uterus. (a) Western blot analysis
of PTEN in whole uterine extracts from Ptenf/f and Ptend/d
mice. (b) Immunohistochemical analysis for PTEN in Ptenf/f and
Ptend/dmice uteri. Four-week-old Ptenf/f and Ptend/d mice were
used for Western blot analysis and immunohistochemical analysis.
These experiments demonstrate that Pten is conditionally ablated
in the uteri of these mice. Scale bar: 50μm. (c) PR-cre mediated
recombinationofK-rasG12D inuterus.ThemutantK-rasG12Dallele
contains a HindIII restriction site engineered in exon 1, which is
absent in the wild-type allele. Therefore, digestion of the 488-bp
products generates 300-bp and 148-bp restriction fragments in the
mutant but not in the wild-type PCR product.
3.3. Development of Endometrial Cancer in Mice with Pten
Ablation and the Oncogenic K-ras Mutation in PR-Expressing
Cells. To investigate the impact of Pten and K-ras signal-
ing on endometrial cancer development and progression,
control, Ptend/d, K-rasG12D, and Ptend/dK-rasG12D mice were
sacriﬁced, excised uteri were weighed, and morphology
was examined at gross and histological levels. Ptend/dK-
rasG12Dmice showed a signiﬁcant increase in uterine weight
at 2 weeks of age compared to control, Ptend/d,a n dK-rasG12D
mice (Figures 3(a) and 3(b)). Ptend/d and Ptend/dK-rasG12D
mice showed a signiﬁcant increase in uterine wet weight
compared to control mice at 4 weeks of age. The uterine
weight of Ptend/d K-rasG12D mice was signiﬁcantly increased
compared to other mice including Ptend/d mice at 4 weeks
of age (Figures 3(a) and 3(b)). The uterine weight of K-
rasG12Dmice did not change compared to control mice at
either timepoint.
Histological analysis of the uteri showed an increase in
the number of endometrial glands and in the gland/stroma
ratio in the uteri of 2-week-old Ptend/d and Ptend/dK-
rasG12D mice (Figure 4); however, the myometrium was
not enlarged. These histological changes demonstrate that
the uteri of 2 week old Ptend/d and Ptend/dK-rasG12Dmice4 Journal of Oncology
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Figure 2: Development of vaginal papiloma and increased apoptosis in K-rasG12D mice. (a) The development of vaginal papiloma. Control
and K-rasG12D mice at 2 months of age. (b) H&E staining of vagina of control and K-rasG12D mice. The histology of these lesions revealed an
abnormal vaginal architecture in the K-rasG12D mice compared to controls. (c) TUNEL assay in the uterus of control and K-rasG12D mice at
2 months of age. The number of apoptotic cells was signiﬁcantly increased in epithelial cells of K-rasG12D uteri compared to controls. Scale
bar: 100μm.
display endometrial hyperplasia, a predisposing factor to
endometrial adenocarcinoma in humans. Thus, even though
theuterineweightofthePtend/dK-rasG12D micewasincreased
compared to the Ptend/d mice, the uteri of Ptend/d and
Ptend/dK-rasG12D mice exhibit a similar hyperplastic pheno-
type at 2 weeks of age.
Interestingly, all of the Ptend/dK-rasG12D mice developed
invasive endometrioid-type endometrial adenocarcinoma by
4 weeks of age. The neoplastic endometrial glands in the
Ptend/dK-rasG12Dmice invaded through the uterine muscle
wall and invaded adjacent structures such as the colon,
pancreas, and skeletal muscle (Figure 3(a)). The Ptend/d
mice displayed endometrial hyperplasia at 4 weeks of age
(Figure 4). Although the Ptend/d mice have been previously
shown to develop endometrial hyperplasia and endometrial
cancer[20],theydidnotdevelopinvasiveendometrialcancer
within 4 weeks of age. Thus, histological analysis showed
that Pten ablation in conjunction with the oncogenic K-
ras mutation dramatically accelerated the development of
endometrial cancer compared to single ablation of either
gene (Figure 4). These results suggest that Pten ablation in
addition tothe oncogenicK-rasmutation dramaticallyaccel-
erated the development of endometrial cancer compared to
single mutation of either gene.
3.4. Down-regulation of P4 Signaling in Mice with Pten
Ablation and the Oncogenic K-ras Mutation. Ablation of
Pten resulted in increased activation of AKT as expected
(Figure 5(a)). To determine if the hyperplastic phenotype
observed was due to altered ovarian steroid hormone
signaling, we examined the expression of ERα and PR in
control, K-rasG12D, Ptend/d,a n dPtend/dK-rasG12D uteri at 2
weeks of age using Western blot analysis. The expression
of ERα was decreased in Ptend/d and Ptend/dK-rasG12D uteri
compared to control and K-rasG12D uteri (Figure 5(a)).
Interestingly, the level of PR, both the PR-A and PR-B
isoforms, was decreased only in the Ptend/d K-rasG12D uteri
compared to control, K-rasG12D,a n dPtend/d uteri at 2 weeks
of age (Figure 5(a)).
To analyze the spatial expression of ERα and PR, we
performed immunohistochemical analysis in control, K-
rasG12D, Ptend/d,a n dPtend/dK-rasG12D uteri at 2 weeks of age.
The expression of ERα was decreased in the endometrial
stroma of Ptend/d K-rasG12D compared to Ptend/d mice.
However, the level of ERα was increased in the epithe-
lium of Ptend/dK-rasG12D compared to Ptend/d mice. These
immunohistochemicalresultssuggestthatthedecreasedlevel
of ERαin the whole uterus was due primarily to decreased
ERα expression in the endometrial stroma (Figure 5(b)).
The spatial expression of PR was altered in the Ptend/d
u t e r ic o m p a r e dt oc o n t r o la n dK-rasG12D mice. Instead of
uniform expression throughout the endometrial epithelium,
PR was localized to the distal regions of the epithelium
in the Ptend/d uteri (Figure 5(c)). However, this strong
PR expression was almost lost in the Ptend/dK-rasG12D
mice.
We next investigated the molecular impact of Pten
ablationandtheoncogenicK-rasmutationontheexpression
of ER target genes (Ltf, Clca3, and C3)i nc o n t r o l ,K-rasG12D,
Ptend/d,a n dPtend/dK-rasG12D uteri at 2 weeks of age. Ltf
and C3 were increased in the Ptend/d mice as compared to
control and K-rasG12D mice (Figure 6). Ltf, Clca3, and C3Journal of Oncology 5
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Figure 3: Development of endometrial cancer in mice with Pten ablation and oncogenic K-ras mutation. (a) Gross anatomy of control,
K-rasG12D, Ptend/d,a n dPtend/dK-rasG12D uteri at 2 and 4 weeks of age. Scale bar: 1cm (b) The ratio of uterine weight to body weight in
control, K-rasG12D, Ptend/d,a n dPtend/dK-rasG12D mice at 2 and 4 weeks of age. Uterine weight was determined for females 2 and 4 weeks old.
Increased uterine weight was observed for Ptend/dK-rasG12D mice after 2 weeks of age. ∗, P<. 05; ∗∗∗, P<. 001, one-way ANOVA followed
by Tukey’s post hoc multiple range test.
were signiﬁcantly increased in the Ptend/dK-rasG12D mice as
compared to Ptend/d mice. Since P4 attenuates E2 regulation
of proliferation and gene expression by regulating the
expression of a yet to be identiﬁed paracrine signal from
the stromal cells to the epithelial cells, the regulation of
the expression of ERα and PR in the endometrial stroma
and epithelium by Pten ablation and the oncogenic K-ras
mutation is critical for the expression of ER target genes and
the tumorigenesis of endometrial cancer.
4. Discussion
Endometrial cancer is the most common gynecological
cancer and has been shown to be associated with mutations6 Journal of Oncology
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Figure 4: Histology of uteri from mice with Pten ablation and oncogenic K-ras mutation. H&E staining of control, K-rasG12D, Ptend/d,a n d
Ptend/dK-rasG12D mice at 2 and 4 weeks of age. Endometrial cancer was induced in the uteri of Ptend/dK-rasG12D mice, but not in other mice
at 4 weeks of ages. Scale bar: 200μm.
in the tumor suppressor Pten and the oncogene K-ras among
others [4]. Previous mouse model studies in the skin, ovary,
and lung suggest that these mutations exert cooperative or
antagonistic eﬀects on tumorigenesis depending upon their
interactions with tissue-speciﬁc factors [28–30]. Dinulescu
et al. generated Pten loss and oncogenic K-ras muta-
tions in ovarian surface epithelium using adenoviral vector
delivery of Cre recombinase [28]. These mice developed
endometriosis and endometrioid ovarian adenocarcinoma.
K-ras mutations occur in a very small percentage of human
cases of ovarian cancer but the mutation is important for the
development of ovarian cancer [31]. However, whether Pten
loss and oncogenic K-ras mutations interact to promote or
inhibit the development of endometrial cancer has not yet
been deﬁned. In order to study the role of Pten and K-ras in
the development of endometrial cancer, we generated mice
in which Pten was ablated and K-ras was activated in the
reproductive tract using the PRCre mouse model [23–25].
PTEN is completely lost or mutated in >50% of primary
endometrioid endometrial cancer [15] and in at least 20%
of endometrial hyperplasias, the precancerous lesions of
the endometrium [15, 16]. Thus, loss of PTEN is a very
early event in the multistep process leading to endometrioid
endometrial cancer. Pten+/− and mice with Pten condition-
ally ablated in the uterus (Ptend/d) develop endometrioid
endometrial adenocarcinoma [20, 32]. This mutation and
subsequent Akt activation results in the activation of ERα-
dependent pathways that play an important role in the
tumorigenesis of endometrial cancer [21]. Introduction of
the oncogenic K-ras mutation into the Ptend/d mice acceler-
ated the tumorigenesis of endometrial cancer as compared
to Pten ablation. The neoplastic endometrial glands in the
doublemutantmiceinvadedthroughtheuterinemusclewall
and invaded adjacent structures such as the colon, pancreas,
and skeletal muscle.
The K-ras mutation alone was not suﬃcient enough to
exert a pathological phenotype in the uterus even though
mutations in K-ras have been consistently identiﬁed in
10%–30% of endometrial cancers [4]. Interestingly, K-
rasG12D mice exhibited abnormal vaginal architecture due to
increased keratinization in the vaginal epithelium resulting
invaginalpapilloma.Thedevelopmentofvaginalpapillomas
confounds its impact on the tumorigenesis of endometrial
cancer. Thus, we have only examined these mice up to
3 months of age without evidence of any hyperplasia or
pathological phenotype in the uterus. To determine why
endometrial cancer failed to develop in the K-rasG12D uteri,
we examined proliferation and apoptosis in these mice.
Proliferation was normal; however, apoptosis was signiﬁ-
cantly increased in the epithelial cells of K-rasG12D uteri
compared to control mice as shown by the TUNEL assay
(Figure 2(c)) and immunohistochemistry of cleaved caspase
3 (data not shown). These results suggest that activation in
K-ras is not suﬃcient for the development of hyperplasia
or endometrial cancer due to increased apoptosis of the
endometrial epithelial cells.
Mutations in the β-catenin gene have been found in
approximately 15%–20% of endometrioid carcinomas, with
nuclear accumulation of the protein found in 38% of cases
[33]. Subsets of endometrial carcinomas, especially those
with nuclear translocation of β-catenin [34], are associ-
ated with squamous morule diﬀerentiation. Some of the
tumors in Ptend/d mice exhibited squamous diﬀerentiation,
which can also be observed in human endometrial cancers
while we did not observed squamous diﬀerentiation in
the tumors from Ptend/dK-rasG12D mice (data not shown).Journal of Oncology 7
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Figure 5:Thedecrease ofPRinthe2-week-old Ptend/dK-rasG12D mice. (a)Western blotanalysis of PTEN,AKT,phosphor-AKT,ERα,andPR
in 2 week old control, K-rasG12D, Ptend/d,a n dPtend/dK-rasG12D mice. (b)-(c) Immunohistochemical analysis of ERα (b) and PR (c) in uteri of
control,K-rasG12D,Ptend/d,andPtend/dK-rasG12D mice.ImmunohistochemicalanalysisofPRshowsthatitisdecreasedinthePtend/dK-rasG12D
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Figure 6: The increase of ERα signaling in the 2-week-old Ptend/dK-rasG12D mice. Real-time RT-PCR analysis of Ltf, Clca3, and C3 was
p e r f o r m e di nu t e rio fc o n t r o l ,K-rasG12D, Ptend/d,a n dPtend/dK-rasG12D mice at 2 weeks of age. The results represent the mean ± SEM of three
independent RNA sets. ∗∗∗, P<. 001, one-way ANOVA followed by Tukey’s post hoc multiple range test.8 Journal of Oncology
Nuclear translocation of β-catenin was not observed in the
Ptend/d mice and Ptend/dK-rasG12D mice (data not shown). It
indicates that the histopathology of the endometrial cancer
lesions in the mice is very similar to human endometrial
cancer but does not totally resemble human endometrial
cancer which is mainly composed of glandular components
with squamous diﬀerentiation.
ER and PR are usually found in high concentration
in endometrial hyperplasia and endometrioid carcinomas
of low grade and stage. However, the level of ER and PR
diminishes with increases in stage and grade [35, 36]. The
level of total ERα was decreased in Ptend/d and Ptend/dK-
rasG12D u t e r ic o m p a r e dt oc o n t r o la n dK-rasG12D uteri using
Western analysis (Figure 5(a)). The amount of epithelial
cells in Ptend/d and Ptend/dK-rasG12D uteri is much higher
than control and K-rasG12D mice because of the hyperplasia
phenotype. The amount of epithelial cells was diﬀerent in
the 4 diﬀerent groups of the Western analysis because we
have not puriﬁed epithelial cells and normalized to epithelial
marker proteins. Therefore, we performed immunohisto-
chemicalanalysistodeterminethesepossiblecompartmental
diﬀerences. The results demonstrated that the expression
of ERα was decreased in the endometrial stroma but
was increased in the endometrial epithelium of Ptend/dK-
rasG12D compared to Ptend/d mice. These results support
that epithelial ERα is important for the tumorigenesis of
endometrial cancer [4].
E2 inducescellproliferation in theluminal andglandular
epithelium. In the uterine luminal epithelium, E2 inhibits
GSK3β action by the stimulation of a protein kinase B-
(AKT)-mediated inhibitory phosphorylation of Ser9. AKT
is in turn regulated through activation of phosphoinositide
3-kinase [37]. P4 inhibits this pathway by blocking AKT
phosphorylation and, thus, the inactivation of GSK3β with
the resultant loss of nuclear cyclin D1 [37]. PR status is
consideredanindependentprognosticfactorforendometrial
cancer patients [38, 39]. PR exists as two isoforms, PR-A
and PR-B, and reduced expression of either one or both of
the PR isoforms has been observed in a great majority of
endometrial cancers, compared with hyperplastic or normal
endometrium [40]. Loss of PR in human endometrioid
endometrial carcinoma results in more aggressive biological
characteristics which play important roles in the prognosis
and recurrence of the disease [40–42]. We observed reduced
expressionofbothPRisoformsinPtend/dK-rasG12D uteri,but
not in Ptend/d or other control uteri. Thus, this loss of PR in
thedoublemutantmicemaybethereasonfortheaccelerated
tumorigenesis of the Ptend/dK-rasG12D mice as compared to
other mice including the Ptend/d mice.
Ourresultsdemonstratethatthesynergisticeﬀectofcon-
ditional Pten loss and oncogenic K-ras mutation on endome-
trial cancer development occurs via decreased expression
of PR. This study has established an endometrial cancer
mouse model which replicates common characteristics of
the human disease. Using this mouse model, further studies
can be undertaken to investigate the genetic and molecular
events involved in the transition from normal to hyper-
plastic/neoplastic endometrium. In summary, these results
greatly contribute to the understanding of the molecular
mechanism of tumorigenesis and to the development of
therapeutic approaches for endometrial cancer.
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